Literature DB >> 21695838

Viral hepatitis: Impact of adherence to combination therapy for hepatitis C.

Yasuji Arase1.   

Abstract

Combination therapy for chronic hepatitis C is associated with adverse effects that can lead to dose reduction or even discontinuation of treatment. A prospective, real-time, observational study by Marcellin and colleagues provides useful information for physicians regarding the role of patient adherence in tailoring patient management and optimizing treatment outcomes.

Entities:  

Year:  2011        PMID： 21695838     DOI： 10.1038/nrgastro.2011.62

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  9 in total

1.  Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

Authors:  Jean-Pierre Bronowicki; Denis Ouzan; Tarik Asselah; Hervé Desmorat; Jean-Pierre Zarski; Juliette Foucher; Marc Bourlière; Christophe Renou; Albert Tran; Pascal Melin; Christophe Hézode; Michelle Chevalier; Magali Bouvier-Alias; Stéphane Chevaliez; François Montestruc; Isabelle Lonjon-Domanec; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2006-07-24       Impact factor: 22.682

2.  Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

Authors:  Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuyuki Araki; Toshiya Osawa; Keiji Kita; Masaharu Ando; Toshinari Shimoe; Kouichi Takaguchi; Noriaki Hashimoto; Toshitsugu Kobatake; Minoru Tomita; Mitsuhiko Kawaguchi; Haruhiko Kobashi; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

3.  Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

Authors:  Mitchell L Shiffman; Marc G Ghany; Timothy R Morgan; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Jules L Dienstag; David R Gretch
Journal:  Gastroenterology       Date:  2006-11-11       Impact factor: 22.682

4.  Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

Authors:  S W Schalm; O Weiland; B E Hansen; M Milella; M Y Lai; A Hollander; P P Michielsen; A Bellobuono; L Chemello; G Pastore; D S Chen; J T Brouwer
Journal:  Gastroenterology       Date:  1999-08       Impact factor: 22.682

5.  Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study.

Authors:  Patrick Marcellin; Michel Chousterman; Thierry Fontanges; Denis Ouzan; Michel Rotily; Marina Varastet; Jean-Philippe Lang; Pascal Melin; Patrice Cacoub
Journal:  Liver Int       Date:  2011-02-15       Impact factor: 5.828

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

9.  Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C.

Authors:  Yasuji Arase; Fumitaka Suzuki; Hitomi Sezaki; Yusuke Kawamura; Yoshiyuki Suzuki; Masahiro Kobayashi; Norio Akuta; Tetsuya Hosaka; Hiromi Yatsuji; Miharu Hirakawa; Mariko Kobayashi; Kenji Ikeda; Hiromitsu Kumada
Journal:  Intervirology       Date:  2008-02-29       Impact factor: 1.763
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.